To spearhead ongoing progress against the stomach cancer, Memorial Sloan Kettering has launched an ambitious program known as the James E. Gerstner Fund for Gastric Cancer Research.
Although less common than it once was in the United States, stomach cancer continues to exact an enormous toll in terms of human lives and suffering. To spearhead ongoing progress against the disease, Memorial Sloan Kettering has launched an ambitious program known as the James E. Gerstner Fund for Gastric Cancer Research.
The initiative is supported by a gift from Louis V. Gerstner, Jr., in memory of his brother. James E. Gerstner was a longtime executive at Bristol-Myers Squibb who died of complications from stomach cancer at age 48.
The James E. Gerstner Fund will under-write key elements of Memorial Sloan Kettering’s comprehensive gastric cancer program, including advanced studies into the biology of the disease. It will also support the Gastric Cancer Registry, which is helping to pinpoint the genetic and environmental causes of stomach cancer.The gift honoring his brother is one of many that Louis V. Gerstner, Jr., has made to the Center, where he serves as Vice Chairman of the Boards of Overseers and Managers and as Chairman of the Sloan Kettering Institute’s Board of Managers